Cbio A/S Due Diligence

Run due diligence on Cbio A/S: check compliance and get alerts when suppliers or ownership change.

Denmark · owned by Independent (Denmark) · www.cbio.dk · 6 vendors

Cbio A/S is a Danish biopharmaceutical company dedicated to developing next-generation T-cell therapies for cancer patients worldwide, with a focus on solid tumors. The company operates a state-of-the-art GMP manufacturing facility in Søborg, Copenhagen, and has developed a proprietary REVITA technology platform designed to produce highly potent, stemness-like T-cell therapy products. Its lead product, novoleucel, is a broad-spectrum T-cell therapy targeting late-stage cancer patients, with clinical trials planned at Karolinska Institute in Stockholm.

Resilience scores

Technology vendors

Insights

Last updated 2026-11-22 · revision 3

6 direct vendors, 130 subvendors

Direct vendors by controlling owner country (sample)

Subvendors by controlling owner country (sample)

Compliance

9 in-scope frameworks identified; showing 3.

EU Good Manufacturing Practice — Evidence found

Cbio A/S manufactures advanced therapy medicinal products for clinical trials in Denmark, which requires adherence to EU GMP standards.

Evidence: https://www.cbio.dk/, https://www.cbio.dk/about, https://www.globenewswire.com/news-release/2026/03/12/3254322/0/en/cbio-a-s-receives-european-regulatory-clearance-to-begin-first-in-human-clinical-trial-of-next-generation-t-cell-therapy-in-late-stage-cervical-cancer.html, https://allsci.com/news/cbio-advances-novoleucel-t-cell-therapy-into-first-in-human-trial-for-recurrent-cervical-cancer/

European Pharmacopoeia — No public evidence

Manufacturing medicinal products under GMP in Europe necessitates compliance with the quality standards for substances and methods defined in the European Pharmacopoeia, which is enforced in Denmark via the Danish Drug Standards (Danske Lægemiddelstandarder).

GDPR (source) — Evidence found

Cbio A/S is established in Denmark (an EU member state) and its website is directed at an international audience, including individuals in the EU/EEA. It processes personal data of website visitors, employees, and business contacts.

Financials

Three-year financials

Financial Resilience Score: 5/10

Cbio A/S is a clinical-stage biopharmaceutical company with the typical financial profile of a pre-revenue biotech: no disclosed product sales, recurring net losses, and dependence on grant funding and equity raises. The company secured a meaningful DKK 28M non-dilutive grant from Innovation Fund Denmark plus DKK 12M in equity, providing runway through 2026 to complete the Phase I/II clinical trial at Karolinska. Solvency at 24.8% in 2025 is considered acceptable, and the company maintains a strong strategic infrastructure including a 1,000 m² Copenhagen cleanroom facility with capacity for up to 150 patients/year (expandable to 600). However, financial resilience is constrained by shrinking equity (DKK 12.3M in 2024 down to DKK 10.5M in 2025), a liquidity ratio flagged as unsatisfactory (current ratio fell from 74.5% to 44.1%), and a return-on-assets of -4.3%. The balance sheet of DKK 42.2M is dominated by liabilities relative to the DKK 10.5M equity base, indicating substantial grant obligations. Pipeline concentration on a single asset (novoleucel) in a single indication (cervical cancer) creates existential clinical risk, and additional capital will be required beyond 2026. The score reflects a company with secured near-term runway but material longer-term financing and execution risks.

Key strengths: DKK 28M non-dilutive grant from Innovation Fund Denmark securing runway to 2026, DKK 12M equity injection from new and existing shareholders, Positive gross profit in each of last three years (DKK 3.67M in 2025), Solvency ratio of 24.8% rated 'God' (good), 1,000 m² state-of-the-art Copenhagen cleanroom facility, Clinical catalyst imminent with Phase I/II trial at Karolinska Hospital in early 2026, Validated research collaborations with BRIC (University of Copenhagen) and Odense University Hospital

Risk factors: Chronic unprofitability with widening net loss (DKK -1.80M in 2025 vs -79.6K in 2024), Equity contracted 15% from DKK 12.3M to DKK 10.5M in 2025, Liquidity flagged 'Ikke tilfredsst.' (unsatisfactory) with current ratio falling to 44.1%, Return-on-assets of -4.3% in 2025 rated unsatisfactory, Single-asset, single-indication pipeline concentration (novoleucel in cervical cancer), No disclosed revenue - pre-commercial stage, Small team of 7-8 employees limits execution bandwidth, Balance sheet dominated by liabilities (DKK 42.2M total assets vs DKK 10.5M equity), Additional capital raises required beyond 2026

Workforce by country

Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.

View the full interactive report